Long-term safety and tolerability of atomoxetine in Japanese adults with attention deficit hyperactivity disorder
Asia-Pacific Psychiatry · 2014-09 · 6 (3) · 292-301
DOI: 10.1111/appy.12119 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Asia-Pacific Psychiatry, online erschienen am 25.12.2013. Verfasst von Yuko Hirata und 6 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly Japan K.K., Lilly Research Laboratories, Kobe, Japan. Hauptthemen laut MEDLINE: Adrenergic Uptake Inhibitors, Propylamines. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eli Lilly Japan K.K., Lilly Research Laboratories, Kobe, Japan.
Förderung
- Eli Lilly and Company
Zitieren
APA
Hirata, Y., Goto, T., Takita, Y., Trzepacz, P. T., Allen, A. J., Ichikawa, H., & Takahashi, M. (2014). Long-term safety and tolerability of atomoxetine in Japanese adults with attention deficit hyperactivity disorder. Asia-Pacific Psychiatry, 6(3), 292-301. https://doi.org/10.1111/appy.12119
Vancouver
Hirata Y, Goto T, Takita Y, Trzepacz PT, Allen AJ, Ichikawa H, et al. Long-term safety and tolerability of atomoxetine in Japanese adults with attention deficit hyperactivity disorder. Asia-Pacific Psychiatry. 2014;6(3):292-301. doi:10.1111/appy.12119
BibTeX
@article{Hirata2014,
author = {Hirata, Yuko and Goto, Taro and Takita, Yasushi and Trzepacz, Paula T and Allen, Albert J and Ichikawa, Hironobu and Takahashi, Michihiro},
title = {Long-term safety and tolerability of atomoxetine in Japanese adults with attention deficit hyperactivity disorder},
journal = {Asia-Pacific Psychiatry},
year = {2014},
volume = {6},
number = {3},
pages = {292--301},
doi = {10.1111/appy.12119}
}
EUVIMED